A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
Public ClinicalTrials.gov record NCT02677116. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination With Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients With Relapsed or Refractory Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of this study is to evaluate the safety of different doses of olaratumab and to determine which dose should be used for future pediatric studies. The present study is open to children with advanced cancer or cancer that has spread to another part of the body. The study has three parts. In the first two parts, a specific dose of olaratumab will be given in 21 day cycles, followed by one of three standard chemotherapy regimens. In the third part, a specific dose of olaratumab will be given with one of three standard chemotherapy regimens in 21 day cycles. Participants will only enroll in one part.
Study identification
- NCT ID
- NCT02677116
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 68 participants
Conditions and interventions
Conditions
Interventions
- Olaratumab Drug
- Doxorubicin Drug
- Vincristine Drug
- Irinotecan Drug
- Ifosfamide Drug
Drug
Eligibility (public fields only)
- Age range
- Up to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 29, 2016 (Actual)
- Primary completion
- Oct 10, 2018 (Actual)
- Completion
- Apr 3, 2019 (Actual)
- Last update posted
- May 20, 2020
2016 – 2019
United States locations
- U.S. sites
- 20
- U.S. states
- 15
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Phoenix Childrens Hospital | Phoenix | Arizona | 85016 | — |
| Childrens Hospital of Los Angeles | Los Angeles | California | 90027 | — |
| University of California, San Francisco | San Francisco | California | 94158 | — |
| The Children's Hospital for Cancer and Blood Disorders | Aurora | Colorado | 80045 | — |
| Children's National Medical Center | Washington D.C. | District of Columbia | 20010-2970 | — |
| Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| Riley Hosptial for Children | Indianapolis | Indiana | 46202 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| University of Minnesota Medical School | Minneapolis | Minnesota | 55455 | — |
| Children's Mercy Hospital | Kansas City | Missouri | 64108 | — |
| Cohen Children's Medical Center | New Hyde Park | New York | 11040 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Levine Children's Hospital | Charlotte | North Carolina | 28203 | — |
| St Jude Childrens Research Hospital | Memphis | Tennessee | 38105 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232-6307 | — |
| Mary Crowley Cancer Research Center | Dallas | Texas | 75230 | — |
| University of Texas Southwestern Medical Center at Dallas | Dallas | Texas | 75235 | — |
| Texas Childrens Hospital | Houston | Texas | 77030 | — |
| Primary Childrens Medical Center | Salt Lake City | Utah | 84132 | — |
| Seattle Children's Hospital Research Foundation | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02677116, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 20, 2020 · Synced Nov 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02677116 live on ClinicalTrials.gov.